Cardio Diagnostics Holdings (NASDAQ: CDIO) is pioneering a new approach to cardiovascular disease detection by integrating artificial intelligence with genetic and epigenetic biomarkers, as highlighted in a recent article. The company aims to address the urgent need for more effective tools to identify risk earlier and guide personalized intervention strategies.
The article, available at https://ibn.fm/Nfps9, notes that Cardio Diagnostics is developing a suite of clinical, population health, and biopharma solutions designed to leverage AI, epigenetics, and genetics to improve cardiovascular disease prevention, detection, and management. The company’s platform is built around the integration of genetic and epigenetic biomarkers with AI-driven analytics to provide personalized cardiovascular insights from blood-based testing.
Cardio Diagnostics currently offers two clinical solutions: Epi+Gen CHD and PrecisionCHD. These tests are designed to assess an individual’s risk of coronary heart disease by analyzing a combination of genetic and epigenetic markers. In addition, the company provides population health and biopharma offerings, HeartRisk and CardioInnovate360, respectively. Collectively, these solutions reflect a strategy aimed at addressing cardiovascular disease across multiple stages of care, from early detection and prevention to therapeutic development and population-level risk management.
The significance of this approach lies in its potential to shift cardiovascular care from a reactive model—where treatment begins after symptoms appear—to a proactive one focused on early risk identification and personalized prevention. Traditional risk assessment tools, such as cholesterol levels and blood pressure, often miss a substantial portion of at-risk individuals. By incorporating genetic and epigenetic data, Cardio Diagnostics aims to uncover hidden risks that conventional methods may overlook.
Cardio Diagnostics, an artificial intelligence-powered precision cardiovascular medicine company, was formed to further develop and commercialize clinical tests by leveraging a proprietary AI-driven Integrated Genetic-Epigenetic Engine, referred to as the Core Technology. The company’s mission is to make cardiovascular disease prevention, detection, and management more accessible, personalized, and precise.
The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO. As with any forward-looking statements, the company cautions that these involve risks and uncertainties, including those set forth under the heading ‘Risk Factors’ in its filings with the SEC. Undue reliance should not be placed on forward-looking statements, and the company undertakes no duty to update this information unless required by law.
This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Cardio Diagnostics Leverages AI and Genetics to Transform Cardiovascular Risk Detection.